• linkedin
  • Increase Font
  • Sharebar

    Top 5 pipeline drugs for 2018

    New blockbuster drugs to treat HIV, diabetes, cancer, migraine headaches and other conditions are expected to be among the top drugs to hit the marketplace in 2018.

    Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.

    1. An upcoming “HIV triplet” drug (bictegravir/FTC/TAF, Gilead Sciences) will be the biggest potential new drug launch of 2018. In mid-2017, Gilead said that four phase 3 studies evaluating a fixed-dose combination of bictegravir (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (FTC/TAF) to treat HIV-1 met their primary objectives of non-inferiority.

    “All indications are that Gilead’s new HIV triplet can reach $5 billion in sales by 2022, based on the strength of their HIV franchise and the company’s willingness to spend resources to remain the market leader as its sales in the hepatitis C market decreases,” John Santilli, president of Access Market Intelligence, told FormularyWatch.

    Related: FDA approves first generic Truvada for HIV

    Plus, Gilead’s “will be working to aggressively convert patients to these more convenient regimens, especially as other products hit patent expiry,”  Leslie Sandberg Orne, senior partner at Trinity Partners, told FormularyWatch. The manufacturer is expected to price the new triplet therapy aggressively, she added.

         2. Semaglutide (Ozempic, Novo Nordisk), a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, is also expected to produce blockbuster sales. FDA approved the New Drug Application (NDA) for semaglutide injection 0.5 mg or 1 mg in late 2017.

    “Novo Nordisk will invest heavily here and this drug is completely in their wheelhouse,” Sandberg Orne said.

    Novo Nordisk’s trials have all demonstrated superiority over existing options in blood glucose and weight control, Sandberg Orne said. “In addition, they studied semaglutide against placebo and demonstrated a positive CV effect. With these data, they expect to steal share from existing GLP-1s, and they’ve set their sights on expanding within the diabetes class with their data that the drug is cardio-protective (a feature that other drugs outside the class cannot claim either).”

         3. Apalutamide (ARN-509), for which Johnson & Johnson submitted a New Drug Application to FDA in October, 2017, “will be the first product available for non-metastatic castration-resistant prostate cancer [CRPC) and specifically targets men with rapidly rising PSA (those at highest risk for metastatic disease),” Sandberg Orne said. 

    Related: New treatment for advanced kidney cancer approved

    Johnson & Johnson has been battling Pfizer for the metastatic prostate cancer market, so ARN-509 would allow Johnson & Johnson to move treatment earlier. “Although they haven’t published the Phase 3 data, they felt confident enough to file with the FDA and early data was strong,” Sandberg Orne said.

         4. Erenumab (Aimovig, Amgen) for migraine headaches is expected to receive FDA approval in 2018. In the fall of 2017, Amgen said that a phase 2 chronic migraine study demonstrated that Aimovig reduced the number of monthly migraine days in patients who have failed previous preventive therapies. In addition, results from a dedicated study in patients with stable angina adds further support to the safety profile of Aimovig, Amgen said.

    “The drug has shown to reduce the length of migraine attacks by half and significantly reduce the frequency of attacks,” Santilli said. In addition, Teva and Eli Lilly & Co. (galcanezumab) will likely receive approval for similar migraine therapies in 2018, according to Santilli.

         5. Emicizumab (Hemlibra, Roche), which was approved in late 2017, “fulfills the long-awaited goal of being once-weekly for hemophilia patients,” Sandberg Orne said.

    The novel drug is also expected to be extremely profitable, with its estimated $482,000 annual wholesale acquisition cost.

    “The product is approved for a subset of the most difficult-to-treat hemophilia patients: those who have inhibitors to standard treatments. Products for these patients command extremely high prices, so we would expect significant sales from this ultra-orphan, high-need population,” Sandberg Orne said.

    Read more: FDA approves hemophilia A drug for children

    2 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • [email protected]
      After my 3rd pulmonary embolism in 2003, I was diagnosed with pulmonary fibrosis and I read that people usually die within 5 years. My specialist has me on blood thinners, prednisone and other steroids that I inhale daily. October 2006 I decided to go with natural treatment and was introduced to Mbeki Herbal Clinic natural organic COPD Herbal formula, i had a total decline of symptoms with this COPD Herbal formula treatment. The infections, shortness of breath, fatigue, dry cough and other symptoms has subsided. Somehow, the herbs managed to keep me alive for 13 years.Visit Mbeki Herbal Clinic official website ww w. mbekiherbalclinic. com or email [email protected] mbekiherbalclinic. com. I have had great improvement with my over all respiration with this product and i breath very much easier, i can never be thankful enough to nature
    • [email protected]
      I was diagnosed with Parkinson's disease in my mid to late 40's. I had hand tremors for several years. Gradually becoming worse. I then noticed when I was tired the tremors were worse. I started falling for no apparent reason. I Later had stiffness in my legs and need to walk with 2 canes or a walker. I was very slow getting around. I am now 54 years old. I was forgetful at times and had difficulty expressing myself. I had difficulty swallowing at times. I become tired easily.Now am Parkinson's disease free,after using the Parkinson's disease herbal formula i purchased from BEST HEALTH HERBAL CENTRE for 6 weeks,tremors disappeared,No more legs stiffness,energy increased,walking without cane. All thanks to God for leading to BEST HEALTH HERBAL CENTRE. please visit their website for more information..